Saturday 17 October 2026
Export ALC’s income statement to Excel — free account
Alcon
ALC Healthcare Medical Instruments & Supplies
Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS fell 100.0%, free cash flow was flat and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
66.18
0.40
−0.60%
Follow ALC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
51.22 | 45.12 | 39.60 | 35.15 |
+8 more quarters Free account |
P/S ratio |
3.01 | 3.45 | 3.74 | 3.61 | |
P/FCF ratio |
20.49 | 23.00 | 24.10 | 26.53 | |
P/Operating CF |
64.03 | 87.82 | 59.07 | 50.76 | |
P/B ratio |
1.51 | 1.66 | 1.76 | 1.66 | |
Price to Tangible BV |
8.03 | 9.18 | 10.30 | 10.04 | |
EV/Sales |
3.31 | 3.74 | 4.04 | 3.93 | |
EV/EBITDA |
13.13 | 15.67 | 16.46 | 15.31 | |
EV/Operating CF |
15.55 | 17.26 | 18.49 | 19.30 | |
EV/FCF |
22.53 | 24.93 | 26.04 | 28.87 | |
Quick Ratio |
1.12 | 1.22 | 1.17 | 1.15 | |
Current Ratio |
2.09 | 2.20 | 2.12 | 2.12 | |
Net Debt/EBITDA |
4.06 | 4.93 | 4.85 | 4.89 | |
Debt/Assets |
15.17% | 14.97% | 15.01% | 15.01% | |
Debt/Equity |
0.22 | 0.21 | 0.22 | 0.21 | |
Asset Turnover |
0.35 | 0.34 | 0.34 | 0.33 | |
Operating CF/Net income |
0.00 | 2.21 | 3.03 | 3.05 | |
Capex/Depreciation |
(0.18) | (0.58) | (0.61) | (0.56) | |
Interest Coverage |
0.21 | 5.62 | 5.91 | 6.51 | |
Research and Development Expense of Revenue |
23.49% | 9.05% | 10.04% | 9.56% | |
Selling, General and Administrative Expense of Revenue |
34.15% | 32.59% | 33.15% | 33.09% | |
Intangible Assets out of Total Assets |
0.56 | 0.57 | 0.58 | 0.58 | |
Share Based Compensation of Revenue |
1.49% | 1.66% | 1.62% | 1.57% | |
Graham Net Nets |
(0.09) | (0.08) | (0.08) | (0.08) | |
Graham Number |
36.16 | 41.32 | 44.73 | 46.22 | |
Earnings Yield |
1.95% | 2.22% | 2.53% | 2.85% | |
Free Cash Flow Yield |
4.88% | 4.35% | 4.15% | 3.77% | |
Revenue per Share |
5.80 | 5.55 | 5.51 | 5.30 | |
Operating CF per Share |
1.05 | 0.86 | 1.33 | 1.47 | |
Capex per Share |
(0.29) | (0.39) | (0.41) | (0.37) | |
Free Cash Flow per Share |
0.76 | 0.47 | 0.93 | 1.09 | |
Cash per Share |
2.99 | 3.41 | 3.26 | 3.04 | |
Shareholders Equity per Share |
44.37 | 45.43 | 44.68 | 44.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
44.37 | 45.43 | 44.68 | 44.79 | |
Free Cash Flow |
370.00 | 227.00 | 457.00 | 540.00 | |
Working Capital |
3,457.00 | 3,616.00 | 3,400.00 | 3,343.00 | |
Capital Expenditures |
(140.00) | (191.00) | (201.00) | (184.00) | |
Net Current Asset Value |
(2,878.00) | (2,866.00) | (3,071.00) | (3,103.00) | |
EV/EBIT |
37.89 | 33.60 | 30.88 | 27.73 | |
Capex to Sales |
0.05 | 0.07 | 0.07 | 0.07 | |
Price to Operating Income |
34.45 | 31.01 | 28.58 | 25.48 | |
| Other line items | |||||
Average Receivables |
2,057.50 | 1,933.50 | 1,860.50 | 1,853.50 | |
Average Payables |
931.50 | 880.50 | 849.50 | 872.00 | |
Average Inventory |
2,452.00 | 2,390.50 | 2,329.50 | 2,405.50 | |
Average Assets |
31,242.50 | 31,313.50 | 30,951.00 | 30,943.00 | |
Average Common Equity |
21,863.00 | 22,076.00 | 21,794.00 | 21,738.50 |
Columns are period end dates